vs
Side-by-side financial comparison of Crinetics Pharmaceuticals, Inc. (CRNX) and Research Solutions, Inc. (RSSS). Click either name above to swap in a different company.
Research Solutions, Inc. is the larger business by last-quarter revenue ($11.8M vs $6.2M, roughly 1.9× Crinetics Pharmaceuticals, Inc.). Research Solutions, Inc. runs the higher net margin — 4.6% vs -1993.4%, a 1998.1% gap on every dollar of revenue. Research Solutions, Inc. produced more free cash flow last quarter ($1.4M vs $-93.4M).
Crinetics Pharmaceuticals is a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018.
Jacobs Solutions Inc. is an American international technical professional services firm based in Dallas. The company provides engineering, technical, professional, and construction services as well as scientific and specialty consulting for a broad range of clients globally, including companies, organizations, and government agencies. Jacobs has consistently ranked No. 1 on both Engineering News-Record (ENR)'s 2018, 2019, 2020, 2021, 2022, and 2023 Top 500 Design Firms and Trenchless Technolo...
CRNX vs RSSS — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $6.2M | $11.8M |
| Net Profit | $-122.8M | $546.9K |
| Gross Margin | — | 52.4% |
| Operating Margin | -2169.6% | 6.3% |
| Net Margin | -1993.4% | 4.6% |
| Revenue YoY | — | -1.0% |
| Net Profit YoY | -52.4% | 127.6% |
| EPS (diluted) | $-1.30 | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $6.2M | $11.8M | ||
| Q3 25 | — | $12.3M | ||
| Q2 25 | $1.0M | $12.4M | ||
| Q1 25 | — | $12.7M | ||
| Q4 24 | $0 | $11.9M | ||
| Q3 24 | $0 | $12.0M | ||
| Q2 24 | — | $12.1M | ||
| Q1 24 | — | $12.1M |
| Q4 25 | $-122.8M | $546.9K | ||
| Q3 25 | — | $749.4K | ||
| Q2 25 | $-115.6M | $2.4M | ||
| Q1 25 | — | $216.5K | ||
| Q4 24 | $-80.6M | $-2.0M | ||
| Q3 24 | $-76.8M | $669.0K | ||
| Q2 24 | — | $-2.8M | ||
| Q1 24 | — | $76.3K |
| Q4 25 | — | 52.4% | ||
| Q3 25 | — | 50.6% | ||
| Q2 25 | — | 51.0% | ||
| Q1 25 | — | 49.5% | ||
| Q4 24 | — | 48.9% | ||
| Q3 24 | — | 47.9% | ||
| Q2 24 | — | 46.5% | ||
| Q1 24 | — | 45.2% |
| Q4 25 | -2169.6% | 6.3% | ||
| Q3 25 | — | 7.8% | ||
| Q2 25 | -12523.0% | 9.7% | ||
| Q1 25 | — | 4.4% | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | 5.4% | ||
| Q2 24 | — | 5.5% | ||
| Q1 24 | — | 0.7% |
| Q4 25 | -1993.4% | 4.6% | ||
| Q3 25 | — | 6.1% | ||
| Q2 25 | -11216.0% | 19.0% | ||
| Q1 25 | — | 1.7% | ||
| Q4 24 | — | -16.6% | ||
| Q3 24 | — | 5.6% | ||
| Q2 24 | — | -23.3% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | $-1.30 | $0.02 | ||
| Q3 25 | — | $0.02 | ||
| Q2 25 | $-1.23 | $0.08 | ||
| Q1 25 | — | $0.01 | ||
| Q4 24 | $-0.86 | $-0.07 | ||
| Q3 24 | $-0.96 | $0.02 | ||
| Q2 24 | — | $-0.09 | ||
| Q1 24 | — | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.0B | $12.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $992.1M | $17.2M |
| Total Assets | $1.1B | $44.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.0B | $12.3M | ||
| Q3 25 | — | $12.0M | ||
| Q2 25 | $1.2B | $12.2M | ||
| Q1 25 | — | $9.9M | ||
| Q4 24 | $1.4B | $7.7M | ||
| Q3 24 | $862.7M | $6.9M | ||
| Q2 24 | — | $6.1M | ||
| Q1 24 | — | $4.2M |
| Q4 25 | $992.1M | $17.2M | ||
| Q3 25 | — | $15.6M | ||
| Q2 25 | $1.2B | $13.9M | ||
| Q1 25 | — | $11.2M | ||
| Q4 24 | $1.3B | $11.1M | ||
| Q3 24 | $833.0M | $12.8M | ||
| Q2 24 | — | $11.7M | ||
| Q1 24 | — | $14.1M |
| Q4 25 | $1.1B | $44.2M | ||
| Q3 25 | — | $45.5M | ||
| Q2 25 | $1.3B | $46.1M | ||
| Q1 25 | — | $45.2M | ||
| Q4 24 | $1.4B | $42.8M | ||
| Q3 24 | $937.4M | $41.4M | ||
| Q2 24 | — | $41.9M | ||
| Q1 24 | — | $40.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-92.9M | $1.4M |
| Free Cash FlowOCF − Capex | $-93.4M | $1.4M |
| FCF MarginFCF / Revenue | -1515.3% | 11.7% |
| Capex IntensityCapex / Revenue | 7.4% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 2.53× |
| TTM Free Cash FlowTrailing 4 quarters | $-311.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-92.9M | $1.4M | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | $-85.9M | $2.3M | ||
| Q1 25 | — | $2.9M | ||
| Q4 24 | $-64.7M | $1.0M | ||
| Q3 24 | $-62.8M | $843.1K | ||
| Q2 24 | — | $2.0M | ||
| Q1 24 | — | $2.0M |
| Q4 25 | $-93.4M | $1.4M | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | $-89.1M | — | ||
| Q1 25 | — | $2.9M | ||
| Q4 24 | $-65.7M | — | ||
| Q3 24 | $-63.4M | — | ||
| Q2 24 | — | $1.9M | ||
| Q1 24 | — | $2.0M |
| Q4 25 | -1515.3% | 11.7% | ||
| Q3 25 | — | 8.8% | ||
| Q2 25 | -8637.5% | — | ||
| Q1 25 | — | 22.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 16.0% | ||
| Q1 24 | — | 16.6% |
| Q4 25 | 7.4% | 0.1% | ||
| Q3 25 | — | 0.1% | ||
| Q2 25 | 310.6% | — | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.1% | ||
| Q1 24 | — | 0.0% |
| Q4 25 | — | 2.53× | ||
| Q3 25 | — | 1.48× | ||
| Q2 25 | — | 0.96× | ||
| Q1 25 | — | 13.36× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.26× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 26.43× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CRNX
| Products | $5.4M | 88% |
| Other | $741.0K | 12% |
RSSS
| Transactions | $6.6M | 56% |
| Platforms | $5.2M | 44% |
